Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time‐trend analysis of R/R HL… Click to show full abstract
Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time‐trend analysis of R/R HL patients who received allogeneic hematopoietic cell transplantation (allo‐HCT) at our center from 2001–2017.
Keywords:
hodgkin lymphoma;
allogeneic hematopoietic;
refractory hodgkin;
relapsed refractory;
cell transplantation
Journal Title: Cancer Medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!